Jonathan E. Lim - 20 Jun 2024 Form 4 Insider Report for Boundless Bio, Inc. (BOLD)

Reporting relationship: Director
Issuer ticker: BOLD
Reported as of: 20 Jun 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Jun 2024, 19:49:55 UTC
Prior SEC filing: 04 Apr 2024
Next SEC filing: 30 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Jessica Oien, Attorney-in-Fact for Jonathan Lim

Key filing fact

Jonathan E. Lim filed Form 4 for Boundless Bio, Inc. (BOLD) on 20 Jun 2024.

Key facts

This page summarizes Jonathan E. Lim's Form 4 filing for Boundless Bio, Inc. (BOLD).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 20 Jun 2024, 19:49.

Change

Previous filing in this sequence was filed on 04 Apr 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BOLD transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +6,610
Change %
Price: $0.000000
Shares after: 6,610
Date: 20 Jun 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,610
Exercise price: $5.50
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option was granted pursuant to the Issuer's 2024 Incentive Award Plan. The stock option vests in 36 substantially equal monthly installments beginning on the first monthly anniversary of June 20, 2024, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.